STANKOVICH THOMAS 4
4 · ReShape Lifesciences Inc. · Filed Jul 6, 2023
Insider Transaction Report
Form 4
STANKOVICH THOMAS
Chief Financial Officer
Transactions
- Sale
Common Stock, $0.001 par value per share
2023-03-31$2.60/sh−109$283→ 5,982 total - Sale
Common Stock, $0.001 par value per share
2023-05-31$2.41/sh−98$236→ 5,788 total - Sale
Common Stock, $0.001 par value per share
2023-04-30$2.36/sh−96$227→ 5,886 total - Purchase
Common Stock, $0.001 par value per share
2023-06-30$1.52/sh+17,702$26,907→ 23,490 total
Footnotes (2)
- [F1]On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.
- [F2]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.45 to $1.54, inclusive. The reporting person undertakes to provide to ReShape Lifesciences Inc., any security holder of ReShape Lifesciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4.